Skip to main content
TipRanks
Go Ultimate75% OFF

TME Pharma N.V. (ALTME) AI Stock Analysis

5 Followers
FR:ALTME

TME Pharma N.V.

(Paris:ALTME)

Select Model
Rating:46Neutral
Price Target:EUR 0.10▼(-3.88% Downside)
Action:reiterated
Date:10/30/26

The overall score is heavily pressured by the company's dire financial state, including insolvency and lack of revenue, which are the most significant risk factors. While the stock exhibits positive short-term technical momentum, this is a secondary factor that does not offset the fundamental risk of financial distress. The negative P/E ratio further confirms the lack of underlying value.

Positive Factors
Focused oncology pipelineA focused oncology pipeline gives TME Pharma a clear strategic identity and concentrates resources on diseases with substantial unmet need. Progress in clinical development could create durable value through differentiated treatment options, although outcomes remain dependent on successful execution and trial results.
Negative Factors
Pre-commercial revenue profileNear-zero revenue means the business has not yet established a commercial earnings base and remains dependent on development milestones rather than recurring product sales. The return to zero revenue in 2025 underscores limited near-term revenue visibility and a long path to self-funded operations.

TME Pharma N.V. (ALTME) vs. iShares MSCI France ETF (EWQ)

-50%-25%0%25%50%75%100%125%150%FR:ALTME+51.47%EWQ-1.35%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 10.01M
Dividend Yield
―
Average Volume (3M)
2.94M
Price to Earnings (P/E)
-5.8
Beta (1Y)
-0.73
Revenue Growth
―
EPS Growth
―
Country
France
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

TME Pharma N.V. Business Overview & Revenue Model

Company Description

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipelin...

How the Company Makes Money

Public, company-specific detail sufficient to describe TME Pharma N.V.’s revenue model and key revenue streams in a factual way is not available in the provided prompt context; therefore: null

TME Pharma N.V. Financial Statement Overview

Summary

Financial health is critically weak. The company has negligible revenue, consistent operating losses, negative equity of -$1.58M indicating insolvency, and deeply negative free cash flow. While the cash burn rate has improved, the business model is not viable without substantial new capital.

Income Statement

15Very Negative

Balance Sheet

2Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue-27.00K019.00K17.00K033.00K
Gross Profit-10.00K-8,000-78.00K-127.00K-92.00K-65.97K
EBITDA-1.24M-2.90M-5.17M-5.07M-11.63M-12.88M
Net Income-1.69M-3.29M-5.72M-6.74M-15.13M-14.45M
Balance Sheet
Total Assets1.18M2.14M3.41M2.49M5.24M9.77M
Cash, Cash Equivalents and Short-Term Investments1.03M2.02M3.25M2.25M4.63M9.48M
Total Debt2.89M2.39M56.00K1.17M4.09M2.44M
Total Liabilities3.79M3.72M1.79M2.79M6.51M5.27M
Stockholders Equity-2.61M-1.58M1.61M-294.00K-1.27M4.51M
Cash Flow
Free Cash Flow-1.38M-3.42M-4.65M-5.65M-12.16M-12.39M
Operating Cash Flow-1.38M-3.42M-4.63M-5.63M-12.14M-12.38M
Investing Cash Flow5,0008,000-21.00K-19.00K-21.00K-14.00K
Financing Cash Flow345.00K2.18M5.66M3.27M7.29M11.50M

TME Pharma N.V. Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.10

Price Trends

50DMA0.11Negative
100DMA0.10Positive
200DMA0.09Positive

Market Momentum

MACD-0.00Positive
RSI44.40Neutral
STOCH12.17Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTME, the sentiment is Neutral. The current price of 0.10 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.11, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 12.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALTME.

TME Pharma N.V. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALTME against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:IPHFR:IPH50NeutralEUR 101.09M-1.77152.56%―-29.48%7.91%
FR:ALCLSFR:ALCLS47NeutralEUR 70.88M-0.85-319.92%―-67.65%-266.05%
FR:ALTMEFR:ALTME46NeutralEUR 10.01M-5.7580.75%―――
FR:TNGFR:TNG46NeutralEUR 192.57M-4.14-29.36%―189.81%38.50%
FR:NANOFR:NANO44NeutralEUR 1.32B-23.5889.71%―――
FR:OSEFR:OSE37UnderperformEUR 35.79M-0.90-96.73%―-96.25%-197.89%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%FR:ALTMEFR:IPHFR:NANOFR:TNGFR:OSEFR:ALCLSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALTME and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALTMETME Pharma N.V.0.100.0453.73%
FR:IPHInnate Pharma S.A.0.91-0.72-44.14%
FR:NANONanobiotix SA25.947.7442.53%
FR:TNGTransgene SA0.69-0.57-45.08%
FR:OSEOSE Immunotherapeutics1.52-3.83-71.60%
FR:ALCLSCellectis SA0.98-3.13-76.13%

TME Pharma N.V. Corporate Events

TME Pharma Details Exclusive NOX-A12 Negotiations With TMS

Nov 10, 2026

TME Pharma N.V. is a biotechnology company with clinical assets in brain cancer and eye diseases. Its main compounds are NOX-A12, an anti-CXCL12 L-RNA aptamer studied in glioblastoma, and NOX-E36, an L-RNA aptamer intended for ophthalmic diseases; th...

GLORIA Team Wins German University Medicine Prize for NOX-A12 Research

Nov 3, 2026

Researchers from six German university medical centers received the 2026 German University Medicine Prize for the GLORIA study, TME Pharma’s Phase 1/2 evaluation of NOX-A12 with radiotherapy in newly diagnosed glioblastoma patients resistant to stand...

TME Pharma Narrows Loss, Secures Funding and Partner Talks to Revive Flagship Cancer Program

Oct 30, 2026

TME Pharma reported its semi-annual 2026 results, showing no revenue and a sharply reduced net loss of €0.51 million amid stringent cost controls, with general and administrative and research and development expenses dropping 79% and 98%, respectivel...

TME Pharma Secures Exclusive Talks With Japan’s TMS to Advance NOX-A12 Glioblastoma Program

Oct 29, 2026

TME Pharma has entered into an exclusive six-month negotiation agreement with Japanese clinical-stage biotech TMS Co., which will form a dedicated subsidiary to finance and advance global development of NOX-A12 for glioblastoma. The non-binding frame...

TME Pharma Extends Debt Maturity and Secures New Bond Financing to 2028

Oct 26, 2026

TME Pharma has extended the maturity of all its outstanding debt from May 2027 to 30 June 2028 and secured two new bond financings, improving financial visibility until the second quarter of 2028. The company is favoring bond over equity funding to c...

TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset

Sep 16, 2026

TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and eye diseases, is centered on two key RNA aptamer assets targeting the tumor microenvironment and fibrotic pathways. The firm is advancing its NOX-A12 program in glio...

TME Pharma moves to license glioblastoma drug NOX-A12 and widens strategic focus

Aug 24, 2026

TME Pharma is advancing late-stage partnering plans for its flagship oncology drug NOX-A12, entering a final evaluation phase with two potential partners for a licensing deal to fund and run a phase 2 trial in glioblastoma. The asset benefits from or...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026